1. Scmitt M, Harbeck N, Daidone MG, Brynner N, Duffy MJ, Foekens JA et al. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol 2004; 25: 1397–1406.
2. Shanafelt TD, Call TG . Current approach to diagnosis and management of chronic lymphocytic leukemia. Mayo Clin Proc 2004; 79: 388–398.
3. Brown KA . Nonmalignant disorders of lymphocytes. Clin Lab Sci 1997; 10: 329–335.
4. Sanchez ML, Almeida J, Vidriales B, Lopez-Berges MC, Garcia-Marcos MA, Moro MJ et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002; 16: 1460–1469.
5. Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R et al. Useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem 1999; 45: 1708–1717.